+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Female Hypoactive Sexual Desire Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 51 Pages
  • May 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5602714
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest disease pipeline guide Female Hypoactive Sexual Desire Disorder - Drugs In Development, 2022, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline landscape.

Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic renal failure, hyper-prolactinaemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

Report Highlights


The publisher's latest pipeline guide Female Hypoactive Sexual Desire Disorder - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 5, 1 and 1 respectively.

Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of TablesList of FiguresIntroduction
Report Coverage
Female Hypoactive Sexual Desire Disorder - Overview
Female Hypoactive Sexual Desire Disorder - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
Assesement by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
Dare Bioscience Inc
Emotional Brain BV
Endoceutics Inc
Kuhnil Pharmaceutical Co Ltd
Ovoca Bio Plc
Palatin Technologies Inc
S1 Biopharma Inc
Female Hypoactive Sexual Desire Disorder - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
History of Events
bremelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
KI-1120 - Drug Profile
Product Description
Mechanism Of Action
KI-1128 - Drug Profile
Product Description
Mechanism Of Action
orenetide - Drug Profile
Product Description
Mechanism Of Action
History of Events
prasterone - Drug Profile
Product Description
Mechanism Of Action
History of Events
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
SIP-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Female Hypoactive Sexual Desire Disorder - Dormant Projects
Female Hypoactive Sexual Desire Disorder - Discontinued Products
Female Hypoactive Sexual Desire Disorder - Product Development Milestones
Featured News
Apr 12, 2022: Freya Pharma Solutions announces appointment of Dr. Jan van der Mooren as chief medical officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD
Feb 22, 2022: Ovoca Bio receives marketing approval for Orenetide for the treatment of hypoactive sexual desire disorder in premenopausal women in Russian Federation
May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)
Mar 24, 2021: Daré Bioscience announces initiation of phase 2b RESPOND study of sildenafil cream, 3.6% in women with female sexual arousal disorder
Jan 05, 2021: Ovoca Bio announces resubmission of Marketing Authorisation Application with Russian Ministry of Health for BP-101
Oct 02, 2020: Update on Marketing Authorisation application for BP-101 in Russian Federation
Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
Dec 11, 2019: Daré Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
Oct 16, 2019: Vyleesi phase 3 data to be presented at the 13th European Society Of Gynecology Congress
Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
Aug 27, 2019: AMAG Pharmaceuticals announces commercial availability of Vyleesi (Bremelanotide Injection)
Aug 06, 2019: Palatin Technologies to present data on Vyleesi at Canaccord Genuity's 39th Annual Growth Conference
Jun 21, 2019: AMAG Pharmaceuticals announces FDA approval of Vyleesi (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
Jun 17, 2019: Daré Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer
List of Tables
  • Number of - Products under Development for Female Hypoactive Sexual Desire Disorder, 2022
  • Number of - Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Dare Bioscience Inc, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Endoceutics Inc, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Ovoca Bio Plc, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies Inc, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by S1 Biopharma Inc, 2022
Female Hypoactive Sexual Desire Disorder - Dormant Projects, 2022
Female Hypoactive Sexual Desire Disorder - Discontinued Products, 2022
List of Figures
  • Number of - Products under Development for Female Hypoactive Sexual Desire Disorder, 2022
  • Number of - Products under Development by Companies, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Dare Bioscience Inc
  • Emotional Brain BV
  • Endoceutics Inc
  • Kuhnil Pharmaceutical Co Ltd
  • Ovoca Bio Plc
  • Palatin Technologies Inc
  • S1 Biopharma Inc